Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | IMAGE subgroup analysis: real-world experience of Isa-Pd in patients with R/R multiple myeloma

Xavier Leleu • 29 Sep 2023
IMS 2023
Multiple Myeloma Antibodies Daratumumab Dexamethasone Isatuximab Pomalidomide
ICARIA-MM

In this video, Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the approval of isatuximab in relapsed/refractory (R/R) multiple myeloma, and shares findings from a subgroup analysis conducted in France exploring the safety and efficacy of isatuximab in combination with pomalidomide and dexamethasone (Isa-Pd) in patients with R/R myeloma in the real-world setting. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Xavier Leleu

Quadruplet regimens in transplant-ineligible NDMM: the new standard of care 3:19
Quadruplet regimens in transplant-ineligible NDMM: the new standard of care
Xavier Leleu • 17 Sep 2025
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM 2:58
The IRAKLIA trial: isatuximab subcutaneous via OBI versus IV in RRMM
Xavier Leleu • 17 Sep 2025
The efficacy and safety of belantamab mafodotin in R/R myeloma treated in the real-world setting 4:41
The efficacy and safety of belantamab mafodotin in R/R myeloma treated in the real-world setting
Xavier Leleu • 8 Dec 2024
HRQoL in patients receiving Isa-VRd versus VRd alone in the IMROZ trial 4:25
HRQoL in patients receiving Isa-VRd versus VRd alone in the IMROZ trial
Xavier Leleu • 8 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals